Mark Hobeika, MD
Surgery · Houston, TXNPI 1215129739
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 50.8% of the total. Reporting peaked in 2020 at $4,674 and has fallen 92.4% since, to $356 in 2025.
Across 140 payments — averaging $131.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$9K
- Transmedics, Inc.$6K
- TELA Bio, Inc.$765
- AbbVie$281
- Gilead$225
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$207
- plus $2K from 27 others
Across 13 payments — averaging $34,263 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Transmedics, Inc.$444K
- Xvivo Perfusion Inc.$2K
What the payments were for
- Consulting fees$5,00027%
- Speaking & faculty fees$480%
- Travel & lodging$9,41751%
- Food & beverage$3,87821%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 20 | $9,322 |
| Transmedics, Inc. | 4 | $5,788 |
| TELA Bio, Inc. | 19 | $765 |
| AbbVie | 16 | $281 |
| Gilead | 10 | $225 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $207 |
| Novartis | 2 | $188 |
| Fujifilm Healthcare Americas Corporation | 2 | $167 |
| Shionogi Inc | 9 | $164 |
| Covidien LP | 2 | $155 |
| AstraZeneca | 6 | $110 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $106 |
| Merck | 6 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Abbott | 1 | $92 |
| Eisai Inc. | 3 | $65 |
| Baxter Healthcare | 2 | $62 |
| Wound Management Technologies, Inc | 1 | $57 |
| Biocompatibles, Inc. | 3 | $53 |
| Madrigal Pharmaceuticals | 3 | $46 |
| Smith+Nephew | 2 | $40 |
| Aroa Biosurgery Incorporated | 1 | $35 |
| Kamada Ltd. | 1 | $30 |
| Teleflex LLC | 1 | $29 |
| Stryker | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Integra Lifesciences Corporation | 1 | $23 |
| Shire North American Group Inc | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Intra-sana Laboratories | 1 | $18 |
| Sanofi | 1 | $17 |
| Mirum Pharmaceuticals, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$12,841
- ORGAN CARE SYSTEM$5,788
- ZORTRESS$124
- Signia$113
How this compares
$18,363 in reported general payments places this provider in the 85th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 11 | $106 |
| Levothyroxine Sodium | 13 | $68 |
| Gabapentin | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other surgery in Houston
- James SuliburkHouston$161K
- Funda MericHouston$141K
- Jonathan StahlHouston$105K
- Richard KnightHouston$103K
- Tanyaradzwa KajeseHouston$92K
- Michael HarkinsTomball$2.7M
- Douglas StoddardAustin$1.4M
- Steven FassAustin$989K
- Vineet ChoudhryAustin$851K
- Andy HawthorneRound Rock$843K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.